3 months ago
LLY
AnalystsEmily FieldEmily Field's Stock Forecasts
AnalystsEmily Field
Sectors:
Industries:
Analyst Ranking
Top 40%
#2123 out of 5334 analysts
Average Return
+14.18%
Win Rate
100%7 out of 7
Risk vs Reward
Poor
Good
Emily Field's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Argenx SeARGX | +27.02% | $295.58 | $375.44 | 2021-10-19 - 2022-10-18 | Strong Buy |
Eli Lilly & CoLLY | +20.95% | $988.87 | $1,196.03 | 2026-05-05 - 2026-07-24 | Strong Buy |
Eli Lilly & CoLLY | +18.48% | $1,009.52 | $1,196.03 | 2026-02-20 - 2026-07-24 | Strong Buy |
Abbvie IncABBV | +15.37% | $224.81 | $259.36 | 2026-02-20 - 2026-07-24 | Strong Buy |
Pfizer IncPFE | +7.92% | $26.65 | $24.54 | 2026-02-20 - 2026-07-24 | Strong Sell |
Emily Field Analyst Color
Get additional color on Emily Field's coverage of popular stocks
5 months ago
MRK
5 months ago
LLY
Emily Field's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Eli Lilly & CoLLY | 2 | Strong Buy | $1,400.00 | +17.05% | Maintains | 3 months ago |
Pfizer IncPFE | 1 | Strong Sell | $25.00 | +1.87% | Initiates Coverage On | 5 months ago |
Merck & Co IncMRK | 1 | Strong Buy | $140.00 | +6.81% | Initiates Coverage On | 5 months ago |
Gilead Sciences IncGILD | 1 | Hold | $155.00 | +19.87% | Initiates Coverage On | 5 months ago |
Bristol Myers Squibb CoBMY | 1 | Strong Buy | $75.00 | +20.79% | Initiates Coverage On | 5 months ago |
Biogen IncBIIB | 1 | Hold | $185.00 | -8.50% | Initiates Coverage On | 5 months ago |
Amgen IncAMGN | 1 | Hold | $350.00 | -6.92% | Initiates Coverage On | 5 months ago |
Abbvie IncABBV | 1 | Strong Buy | $275.00 | +6.03% | Initiates Coverage On | 5 months ago |
Argenx SeARGX | 1 | Strong Buy | N/A | N/A | Upgrades | 5 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.